A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502137-26-00

Acronym

R5837-ONC-2019

Enrollment

Registered

2023-08-23

Start date

2024-05-03

Completion date

Unknown

Last updated

2025-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell Non-Hodgkins Lymphoma (B-NHL)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026